Latham & Watkins advised Seres Therapeutics, while Mayer Brown represented Société des Produits Nestlé on the deal. Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics...
Seres Therapeutics’ VOWST Asset Purchase Agreement With Nestlé Health Science
Illumina’s Divestiture of GRAIL
Cravath, Swaine & Moore represented Illumina, Inc. on the transaction, and Latham & Watkins represented GRAIL, LLC. GRAIL, Inc. (NASDAQ: GRAL, formerly GRAIL, LLC), a healthcare...
Janux Therapeutics’ $296.5 Million Common Stock Offering
Cooley advised Janux Therapeutics on the offering and Wilson Sonsini Goodrich & Rosati advised Janux on patent matters. Latham & Watkins advised the underwriters. Janux Therapeutics,...
Alpine Immune Sciences’ $150 Million Common Stock Offering
Wilson Sonsini Goodrich & Rosati advised Alpine Immune Sciences on the offering, and Latham & Watkins advised the underwriters. Alpine Immune Sciences, Inc. (Nasdaq: ALPN) announced the...
Boston Scientific’s $850 Million Acquisition of Relievant MedSystems
Faegre Drinker advised Boston Scientific, and Latham & Watkins advised Relievant MedSystems on the deal. Boston Scientific Corporation (NYSE: BSX) announced it has entered into a...
Neumora Therapeutics’ $250.1 Million Initial Public Offering
Latham & Watkins advised Neumora, and Cooley advised the underwriters. Neumora Therapeutics, Inc. announced the pricing of its initial public offering of 14,710,000 shares of its common...
Gilead’s $2 Billion Senior Unsecured Notes Offering
Davis Polk advised Gilead, and Latham & Watkins advised the underwriters. Gilead Sciences, Inc. (Nasdaq: GILD) announced the pricing of senior unsecured notes in an aggregate...
Revolution Medicines’ Acquisition of EQRx
Latham & Watkins advises Revolution Medicines on the deal, and Goodwin Procter advises EQRx. Revolution Medicines, Inc. (Nasdaq: RVMD) and EQRx, Inc. (Nasdaq: EQRX) announced a definitive agreement...
Korro Bio and Frequency Therapeutics’ Merger Agreement
Goodwin Procter is serving as legal counsel to Korro Bio, Latham & Watkins is serving as Frequency Therapeutics’ legal counsel, and Davis Polk is serving as...
4D Molecular Therapeutics’ License Agreement with Astellas Pharma
Latham & Watkins advises 4D Molecular Therapeutics on the deal. Astellas Pharma Inc. (TSE: 4503) and 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) have announced a license...
Gurnet Point Capital’s Acquisition of Paratek Pharmaceuticals
Latham & Watkins advises Gurnet Point Capital in acquisition of Paratek Pharmaceuticals. Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of...
IDEAYA Biosciences’ $175 Million Common Stock Public Offering
Latham & Watkins represents IDEAYA Biosciences in the offering. IDEAYA Biosciences, Inc. (Nasdaq:IDYA) has announced the pricing of an underwritten public offering of common stock and...